Microbiome Therapeutics Market Size - By Type, By Application- Global Forecast, 2025 - 2034

Microbiome Therapeutics Market Size

The global microbiome therapeutics market was valued at USD 212.1 million in 2024 and is expected to reach USD 3.2 billion by 2034, growing at a CAGR of 31.1% from 2025 to 2034. The high market growth can be attributed to the increasing research and development investment and partnership for drug development, fast-track drug approvals and growth in personalized medicine, among other contributing factors.
 

The increasing prevalence of chronic diseases such as gastrointestinal disorders, metabolic disorders and neurological disorders, is a major factor for the growth in adoption of microbiome therapeutics. For instance, according to the Centre for Disease Control and Prevention (CDC) in 2024 an estimated 129 million people in U.S. suffered from at least one major chronic disease, this trend is expected to increase steadily. This increasing number of chronic disorders thrives in the need to develop innovative treatment solutions catering to the growing disease burden thereby enhancing the patient’s outcome.
 

Moreover, growing advancements in microbiome diagnosis and therapies further bolster market growth. For example, research conducted on enhancing the iROBOT therapy system that receives inflammatory signals from the host and target the corresponding tissues for therapy. In addition, breakthroughs such as single-cell analysis through genomic, transcriptomic, and spatial techniques are also important. These technologies have been used in microbiome research and have contributed to advancing understanding of the responses of the host, the microbial diversity and composition, and the host-microbes interactions. This likely increases the rate of diagnosis which in turn increases placed for sophisticated therapeutics and thus expands microbiome therapeutics market growth.
 

Engineered bacteria, live biotherapeutics and microbiome-modulating drugs are used in microbiome therapeutics to treat a variety of chronic conditions. These therapeutics include microbiome drugs and fecal microbiome transplant (FMT). These therapies are gaining attention due to its benefits for immune system regulation, gastrointestinal health, metabolic disorders and oncology.
 

Microbiome Therapeutics Market Trends

The continuous innovations in microbiome technology, growing regulatory approvals, public health initiatives and clinical advancements are some of the key factors boosting the industry growth.
 

• The growing research efforts accelerated faster regulatory approvals, leading to the introduction of effective treatment addressing the growing market demand.
   
• For instance, in April 2023, Seres Therapeutics was granted approved by the Food and Drug Administration (FDA) for VOWST, an orally administered live biotherapeutic treatment for the treatment of recurrence of Clostridioides difficile (C. difficile) infections in adults. This product approval marked an advancement in microbiome drug development catering to the recurrence of condition.
   
• Additionally, public health initiatives and increasing awareness about gut-brain connections are further driving microbiome therapeutics market growth.
   
• For instance, Novo Nordisk Foundation introduced a Microbiome Health Initiative, a research initiative aimed to establish connections between gut microbiome and cardiometabolic diseases to develop a new treatment and preventive options. This strategic initiative aimed to expand awareness prompting for effecting treatment options among the patients with cardiovascular disease (CVD).
   

Moreover, growing advancement, research fundings and accelerated pipeline studies are the factors responsible for further stimulating the market growth.
 

Trump Administration Tariffs

• The tariffs on imports from China, particularly affecting biotechnology raw materials, active pharmaceutical ingredients (APIs), fermentation equipment, and laboratory consumables, has the potential to significantly raise production costs for companies in the microbiome therapeutics market.
• Given that many biotech manufacturers rely on Chinese suppliers for cost-effective production of microbial strains and specialized fermentation substrates, these tariffs can disrupt both supply chains and pricing structures.
   
• In response to these trade barriers, microbiome-focused pharmaceutical companies are increasingly compelled to diversify their supplier base and reduce reliance on Chinese imports. This is driving a gradual shift toward sourcing raw materials and manufacturing equipment from alternative regions such as India, South Korea, the European Union, and Southeast Asia, where supply chains are perceived as more resilient and less vulnerable to trade policy shifts.
   
• Moreover, short-term challenges include extended lead time for raw materials, higher logistics and compliance costs. Additionally, companies are facing potential disruptions in technical support and replacement parts for lab scale bioprocessing system, many of which are sourced or assembled in China.
   

Microbiome Therapeutics Market Analysis

Based on type, the market is classified into fecal microbiota transplantation (FMT) and microbiome drugs. The fecal microbiota transplantation (FMT) segment generated the highest revenue of USD 158.3 million in 2024 and is projected to reach USD 2.3 billion by 2034, witnessing its prominence throughout the forecast period at a CAGR of 30.7%.
 

• FMT is a clinically proven procedure demonstrating positive results in treating recurrent C. difficile infections, outperforming antibiotics.
   
• According to research studies, the FMT has gained nearly 85% - 95% success rate resulting in a promising treatment option widely accepted for C. difficile.
   
• Furthermore, FMT is being studied for its potential application in treating metabolic disorders, oncology and neurological conditions, broadening its clinical relevance.
   
• In addition, the widespread adoption of FMT coupled with expanding FMT programs in hospitals and clinics has made it a viable treatment option to treat several conditions.
   

Based on application, the microbiome therapeutics market is classified into inflammatory bowel disease (IBD), cancer, clostridioides difficile (C.difficile), diabetes and other application. The C. difficile segment accounted for the highest market share of 39.4% in 2024 and is anticipated to grow at a CAGR of 31.6% between the 2025 to 2034 period.
 

• C. difficile infection severity leads to life-threatening conditions such as sepsis, toxic megacolon or colitis impacting the patient’s life.
   
• It is one of the most common hospital-acquired infections (HAIs), particularly in long-term stays. Infection control and reduced hospital readmission costs being a priority for healthcare systems, microbiome-based therapies are seen as preventive and cost-effective treatment options.
   
• According to research studies, the C. difficile incidence rate was found to be 30% - 40%. In addition, the high recurrence rate for C. difficile infection with traditional antibiotics, nearly 25-30% of patients experience recurrent infection. This has prompted the need for effective treatment options, driving the demand for microbiome-based therapies to restore the gut flora and build the immune system.
   

In 2024, U.S. microbiome therapeutics market accounted for USD 85.3 million market revenue in 2024 and is anticipated to grow at a CAGR of 30.1% between the 2025 to 2034 period.
 

• The increasing cases of gastrointestinal and metabolic disorder is a significant factor for the growth of the market in the country. For instance, according to Centre for Disease Control and Prevention, C. diff is considered to infect close to half a million individuals in the U.S. annually. However, individuals with weakened immune systems such as organ transplant patients on immunosuppressive therapy, as well as those afflicted with human immunodeficiency virus (HIV)/AIDS or cancer are highly affected with this infection. The increasing chronic disease prevalence expects to propel the demand for effective therapeutics thereby driving the market demand.
   
• Additionally, the presence of major biotech companies heavily investment in innovative drug development  further fuels the market growth.
   
• Furthermore, growing awareness about the role of gut microbes in immune function and metabolic health among U.S. physicians, increases the adoption of microbiome-based treatments.
   

Germany microbiome therapeutics market is projected to grow remarkably in the coming years.

• The rising burden of chronic diseases in Germany substantial drives demand for microbiome-based treatments.
   
• According to National Institute of Health (NIH), over 320,000 people in Germany suffer from IBD, and C. difficile infections affect around 27,000 patients annually. These findings resulted in the prompting need for effective treatment options to enhance the patient outcomes.
   
• Government’s heavy investment in microbiome research and development through initiatives like the Federal Ministry of Education and Research (BMBF) funding programs, further advances microbiome research activities driving market growth.
   
• Moreover, increasing regulatory support for the microbiome-based therapies, providing special designations and accelerated approval pathways for microbiome drugs, is another significant factor for the market growth.
   

Japan is poised to grow at a significant growth in the Asia Pacific microbiome therapeutics market.
 

• Japan's has one of the world’s oldest populations, with 29.1% of individuals over 65 years old in 2023 according to the Ministry of Internal Affairs and Communications, contributing to the rise of diseases such as cancer, diabetes, and inflammatory bowel disease further driving demand for microbiome-based therapies targeting age-related disorders.
   
• Japan is investing heavily in artificial intelligence (AI) and precision medicine to map the gut microbiome’s impact on diseases, encouraging market growth
   
• Japanese companies such as Yakult Honsha and Morinaga Milk Industry are expanding into microbiome-targeted nutraceuticals and pharmaceuticals to bridge the gap between preventive and therapeutic applications, accelerating the market growth.
   

Brazil held a prominence position in the Latin America microbiome therapeutics market.
 

• Brazil’s high prevalence population suffering from infectious and gastrointestinal diseases, due to poor sanitation in some areas. According to a study conducted by the Journal of Pediatric Gastroenterology and Nutrition in 2022, the incidence of IBD is rising from 9.4 to 9.6 per 100,000 in 2020, requiring advanced microbiome solutions. These rising cases expect to drive the demand for potential treatment options in the country.
   
• In addition, rising cases of obesity raise concerns for the development of weight related disorders. Brazilian researchers and biotech companies are developing microbiome-based solutions to address metabolic disorders that may develop due to the increased obesity.
   
• Increasing investment in research and academic collaborations to develop cutting-edge microbiome research, shapes the scientific foundation for microbiome-based treatments in Brazil.
   

Saudi Arabia’s microbiome therapeutics market is poised to grow at a considerable growth rate in Middle East and Africa market.
 

• As a part of Vision 2030 Saudi Arabia is heavily investing in pharmaceuticals, biotechnology and precision medicine driving microbiome research and therapeutics.
   
• Saudi Arabia is giving greater emphasis on personalized healthcare resulting in increased adoption of microbiome-based functional foods, probiotics, and therapeutic interventions.
   
• Increasing partnerships and collaborations with global biotech firms to bring microbiome-based innovations into the region pose to be a significant factor for market growth.
   

Microbiome Therapeutics Market Share

The top five companies in the global microbiome therapeutics industry accounted for approximately 75-80% of the market share. Leading pharmaceutical and biotech companies such as Seres Therapeutics, Vedanta Biosciences Ferring Pharmaceuticals, Openbiome, and MaaT Pharma hold a strong position due to their advanced microbiome-based drug pipelines and extensive research collaborations.
 

Companies like Seres Therapeutics lead the market with their FDA-approved microbiome oral drugs such as Vowst, indicated to prevent recurrent C. difficile infections. The market is highly competitive, with key players focusing on clinical advancements, innovation and strategic partnerships. In addition, growing regulatory approvals, RESEARCH AND DEVELOPMENT investments and increasing strategic collaboration are anticipated to expand the market share.
 

Microbiome Therapeutics Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development.
 

Prominent players operating in the microbiome therapeutics industry are as mentioned below:

• Aardvark Therapeutics
• AOB Pharma
• Enterome
• Ferring pharmaceuticals
• Finch
• Inlife
• Intralytix
• LNC Therapeutics
• MaaT Pharma
• OPENBIOME
• Seres Therapeutics
• VEDANATA Biosciences
   
• Seres Therapeutics focuses on developing microbiome therapeutics based on live biotherapeutic products (LBPs). With Vowst (SER-109) becoming the first FDA-approved oral microbiome therapeutic for recurrent C. difficile infection, Seres has showcased its clinical leadership and regulatory expertise in microbiome drug development.
   
• Ferring Pharmaceuticals has been able to maintain a strong foothold in the industry with its product Rebyota, the first FDA-approved fecal microbiota-based treatment for C. difficile infections. The company emphasizes biologics and microbiome restoration using donor-derived microbial therapies, along with extensive global manufacturing and distribution capabilities.
   
• VEDANTA Biosciences is focused on developing defined bacterial consortia as microbiome therapeutics using pure, clonal cell strains. The company has extended its pipeline in microbiome research focusing on VE303 for C. difficile and VE202 for IBD.
   

Microbiome Therapeutics Industry News

• In November 2024, AstraZeneca invested USD 3.5 billion in expanding its research and manufacturing footprint in the U.S. This manufacturing facility will focus on developing advancements in microbiome therapies, expanding the company’s portfolio.
   
• In April 2023, the U.S. Food and Drug Administration (FDA) marked a pivotal advancement in microbiome-based therapeutics by approving SER-109, the first oral microbiome drug developed by Seres Therapeutics, indicated to treat recurrent Clostridioides difficile infections.
   
• In January 2022, BiomeBank and Hudson Institute entered into a 4-year collaboration agreement to discover and develop microbial therapies. This partnership will help in identifying key microbial strains which play a role in IBD and develop safe and effective microbial therapy for patients.
   

The microbiome therapeutics market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Fecal microbiota transplantation (FMT)
• Microbiome drugs

Market, By Application

• Inflammatory bowel disease (IBD)
• Cancer
• Clostridioides difficile (C. difficile)
• Diabetes
• Other applications

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE